Posted by Michael Wonder on 17 Jun 2021
Furore rages over FDA approval of controversial Alzheimer’s drug
17 June 2021 - Critics attack the agency’s action as reckless, but defenders say patients will benefit.
Marc Archambault smiled broadly Wednesday as he walked to the microphones at Butler Hospital in Providence, R.I. The silver-haired real estate agent was about to become the first person outside of a clinical trial to be treated with a new Alzheimer’s drug in almost two decades.
“Obviously, I am very happy to have this,” said Archambault, 70, who is in an early stage of the disease. “It’s amazing.”
